Skip to main content

Saturn V Capital Management LP

13F filer · CIK 0001964437
Reported Aug 14, 2026
Net buyer this quarter
13F portfolio value$697MU.S. long equity reported on 13F
Positions233 new · 1 closed
Net flow last quarter+$44.8MBuys minus sells
Top 10 positions weight75.6%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202623 positions
AMLXAmylyx Pharmaceuticals, Inc.$83M11.91%4.15%+6.3%Q3 2023
ALMSAlumis Inc.$82M11.76%Not reported-9.0%Q4 2025
ABVXAbivax S.A.$69.1M9.91%0.66%-4.4%Q1 2024
PCVXVaxcyte, Inc.$49.6M7.11%0.59%+3.4%Q1 2024
IMMXImmix Biopharma, Inc.$48M6.89%6.51%+26.1%Q4 2025
PHVSPharvaris N.V.$45.4M6.52%2.02%+9.4%Q3 2025
JAZZJazz Pharmaceuticals plc$38.8M5.56%0.26%-1.2%Q2 2025
CELCCelcuity Inc.$38.7M5.55%0.76%+31.4%Q2 2024
IRONDisc Medicine, Inc.$38.4M5.50%1.37%+16.6%Q4 2023
CADLCandel Therapeutics, Inc.$34M4.88%4.34%+14.1%Q1 2026
XFORX4 Pharmaceuticals, Inc$32.6M4.67%7.26%+8.0%Q4 2025
MNPRMonopar Therapeutics$28.9M4.14%4.65%-9.7%Q3 2025
DYNDyne Therapeutics, Inc.$23.5M3.37%0.64%+9.4%Q2 2025
TRVITrevi Therapeutics, Inc.$19.6M2.81%0.74%NewQ2 2026
ZURAZura Bio Ltd$12.4M1.78%2.20%+184.0%Q1 2026
SGMTSagimet Biosciences Inc.$11.4M1.64%4.82%NewQ2 2026
OCSOculis Holding AG$9.5M1.36%Not reported+32.5%Q4 2025
IKTInhibikase Therapeutics, Inc.$7.85M1.13%2.93%+0.2%Q4 2025
VIRVir Biotechnology, Inc.$7.85M1.13%0.46%NewQ2 2026
IVVDInvivyd, Inc.$7.32M1.05%2.85%-23.4%Q4 2025
ANROAlto Neuroscience, Inc.$4.82M0.69%0.52%+105.4%Q1 2026
MSLESatellos Bioscience Inc.$2.72M0.39%27.17%Not reportedQ1 2026
OVIDOvid Therapeutics Inc.$1.78M0.26%0.36%-84.1%Q4 2025
Q1 2026Reported May 15, 202621 positions
ALMSAlumis Inc.$70.5M12.77%Not reported+2.1%Q4 2025
AMLXAmylyx Pharmaceuticals, Inc.$60.5M10.95%3.92%-3.3%Q3 2023
ABVXAbivax S.A.$60.4M10.94%0.69%-16.4%Q1 2024
PCVXVaxcyte, Inc.$47.9M8.68%0.57%+3.2%Q1 2024
PHVSPharvaris N.V.$33.9M6.15%1.84%+5.4%Q3 2025
IMMXImmix Biopharma, Inc.$33.6M6.09%6.97%+23.2%Q4 2025
CELCCelcuity Inc.$32.2M5.83%0.58%-11.1%Q2 2024
JAZZJazz Pharmaceuticals plc$30.8M5.58%0.26%-34.3%Q2 2025
IRONDisc Medicine, Inc.$28.8M5.21%1.18%+50.8%Q4 2023
XFORX4 Pharmaceuticals, Inc$26.7M4.83%6.85%+11.3%Q4 2025
COGTCogent Biosciences, Inc.$24.1M4.37%0.37%-48.5%Q2 2023
MNPRMonopar Therapeutics$18.9M3.43%5.16%+6.1%Q3 2025
DYNDyne Therapeutics, Inc.$17.5M3.17%0.59%-46.0%Q2 2025
IVVDInvivyd, Inc.$14.2M2.58%3.87%+41.6%Q4 2025
CADLCandel Therapeutics, Inc.$14.2M2.57%3.95%NewQ1 2026
OCSOculis Holding AG$13.7M2.49%Not reportedNot reportedQ4 2025
OVIDOvid Therapeutics Inc.$9.25M1.68%2.49%+66.7%Q4 2025
IKTInhibikase Therapeutics, Inc.$6.49M1.18%2.93%+0.2%Q4 2025
ZURAZura Bio Ltd$4.4M0.80%0.78%NewQ1 2026
ANROAlto Neuroscience, Inc.$2M0.36%0.25%NewQ1 2026
MSLESatellos Bioscience Inc.$1.97M0.36%27.17%NewQ1 2026
Q4 2025Reported Feb 17, 202620 positions
ABVXAbivax S.A.$87.5M16.07%0.83%-19.0%Q1 2024
AMLXAmylyx Pharmaceuticals, Inc.$54.3M9.97%4.09%-2.4%Q3 2023
COGTCogent Biosciences, Inc.$43.2M7.93%0.76%-39.9%Q2 2023
JAZZJazz Pharmaceuticals plc$42.2M7.74%0.40%-17.5%Q2 2025
PCVXVaxcyte, Inc.$36.9M6.77%0.61%+1.3%Q1 2024
DYNDyne Therapeutics, Inc.$35M6.42%1.08%-33.1%Q2 2025
PHVSPharvaris N.V.$31.6M5.81%1.75%+28.6%Q3 2025
CELCCelcuity Inc.$31.6M5.80%0.66%-33.1%Q2 2024
ALMSAlumis Inc.$30.6M5.62%Not reportedNewQ4 2025
IRONDisc Medicine, Inc.$23.7M4.35%0.79%-12.5%Q4 2023
XFORX4 Pharmaceuticals, Inc$23.2M4.26%6.38%NewQ4 2025
MNPRMonopar Therapeutics$21.3M3.90%4.87%+109.6%Q3 2025
IVVDInvivyd, Inc.$19.1M3.51%2.74%NewQ4 2025
OCULOcular Therapeutix, Inc$18.3M3.35%0.70%+30.7%Q4 2024
IMMXImmix Biopharma, Inc.$15.7M2.88%5.66%NewQ4 2025
OCSOculis Holding AG$10.3M1.89%Not reportedNewQ4 2025
IKTInhibikase Therapeutics, Inc.$7.91M1.45%2.93%NewQ4 2025
CNTACentessa Pharmaceuticals PLC$7.07M1.30%0.19%-61.5%Q1 2025
OVIDOvid Therapeutics Inc.$4.08M0.75%1.92%NewQ4 2025
IVAInventiva S.A.$1.32M0.24%0.15%NewQ4 2025
Q3 2025Reported Nov 14, 202517 positions
ABVXAbivax S.A.$68M14.92%1.26%+28.7%Q1 2024
AMLXAmylyx Pharmaceuticals, Inc.$62.6M13.72%4.20%+41.2%Q3 2023
JAZZJazz Pharmaceuticals plc$39.6M8.69%0.50%+45.3%Q2 2025
DYNDyne Therapeutics, Inc.$33.8M7.42%1.88%+83.8%Q2 2025
COGTCogent Biosciences, Inc.$29.1M6.38%1.45%-11.9%Q2 2023
PCVXVaxcyte, Inc.$28.4M6.23%0.61%+44.9%Q1 2024
CELCCelcuity Inc.$23.4M5.13%1.09%-60.0%Q2 2024
CGONCG Oncology, Inc.$23.4M5.12%0.74%-1.2%Q3 2024
IRONDisc Medicine, Inc.$22.5M4.94%0.97%-13.9%Q4 2023
PHVSPharvaris N.V.$22.1M4.85%1.63%NewQ3 2025
XENEXenon Pharmaceuticals Inc.$20.2M4.44%0.65%+7.5%Q4 2024
CNTACentessa Pharmaceuticals PLC$17.8M3.91%0.55%-7.4%Q1 2025
MRUSMerus N.V.$17.3M3.80%0.24%-17.9%Q3 2023
LENZLENZ Therapeutics, Inc.$17.1M3.76%1.29%+7.6%Q2 2025
OCULOcular Therapeutix, Inc$13.5M2.95%0.66%+58.1%Q4 2024
MNPRMonopar Therapeutics$12.7M2.78%2.33%NewQ3 2025
NAMSNewAmsterdam Pharma Co N.V.$4.36M0.96%0.14%-30.6%Q4 2024
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.